Brief: Mankind Pharma March-Quarter Consol Profit From Continuing Operations 5.59 Billion Rupees
19/05/2026 14:59
May 19 (Reuters) - Mankind Pharma Ltd MNKI.NS: MANKIND PHARMA MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 5.59 BILLION RUPEES MANKIND PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 34.43 BILLION RUPEES MANKIND PHARMA - APPROVED ADDITIONAL INVESTMENT OF UP TO 5 BILLION RUPEES IN MANKIND MEDICARE , IN ONE OR MORE TRANCHES Further company coverage: MNKI.NS ((reuters.briefs@thomsonreuters.com;))
Recent news on Mankind Pharma
See all newsIndia's Mankind Pharma heads for best day in over 3 years as Q2 hints at recovery
Mankind Pharma's quarterly profit jumps 39% on strong chronic drug demand
India's Mankind Pharma gains on higher quarterly profit
Brief: Mankind Pharma Says To Buy 70% Majority Stake In Armed Cell Therapeutics Through Unit
Kotak upgrades India's Mankind Pharma to 'buy' on signs of business recovery